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doi:10.1016/j.jfma.2011.09.008Background/Purpose: In limb reconstruction following resection of malignant bone tumors in
children, extendable prostheses are considered to be useful since future leg length correction
can be controlled. We evaluated the usefulness of extendable prostheses in 11 such cases.
Methods: The study included 11 children aged 7e16 years (mean 11 years) who underwent limb
reconstruction using an extendable prosthesis between 1994 and 2008. The follow-up period
varied from 1 to 16 years (mean 6 years and 2 months). Nine patients had osteosarcoma,
one had a primitive neuroectodermal tumor (PNET) and one had Ewing’s sarcoma. The tumor
was located in the distal femur, (n Z 6), proximal femur (n Z 1), or proximal tibia (n Z 4).
Functional scores, X-ray images, the number of lengthening procedures, total length gain,
complications, and leg length discrepancy were recorded for each patient.
Results: The functional scores range from 52% to 96% (mean 84%). X-Ray evaluation revealed fair
and poor bone remodeling in three patients each. Themean number of elongation procedures was
2.8 and the mean total length gain was 49.7 mm. The final leg length discrepancy was 29.2 mm.
Conclusion: Extendable bone prostheses are useful for reconstruction. According to our
experience, this method is indicated in children of at least 10 years of age for whom a future
leg-length discrepancy of up to 4 cm is expected andwho have a lesion located in the distal femur
where the prosthesis can be adequately covered by soft tissue.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.of Orthopedic Surgery, Nihon University School of Medicine, 30-1, Oyaguchikami-cho, Itabashi-ku,
on-u.ac.jp (Y. Yoshida).
ight ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
712 Y. Yoshida et al.In limb reconstruction following resection of malignant bone
tumors in children, physis loss affects anticipated leg-length
discrepancy. Therefore, joint function should be preserved
to the maximum extent possible and reconstruction assuring
permanent good function of the affected limb should
be carried out. In particular, extendable prostheses are
considered to be useful for reconstruction in children with
malignant bone tumors to allow future correction of leg-
length discrepancy.1e8 In cooperation with the Japanese
Musculoskeletal Oncology Group (JMOG), we previously
studied short-term results obtained with extendable pros-
theses in 28 patients in Japan, and confirmed their useful-
ness.9 In our department, 11 patients have undergone
reconstruction of an affected limb using an extendable
prosthesis, and some have been followed up formore than 10
years. However, problems associated with extendable pros-
theses have arisen. Therefore, we present our treatment
results, indications for extendable prostheses, and a brief
review of the literature.Patients and methods
The patients were 11 children with a malignant bone tumor
of the lower limb who underwent reconstruction with an
extendable prosthesis at our department between 1994 and
2008. They ranged in age from 7 to 16 years (mean 11
years). The follow-up period was 1e16 years (mean 6 years
and 2 months). The Enneking surgical stage was IIB in all
patients. The histopathological diagnosis was osteosarcoma
in nine patients, primitive neuroectodermal tumor (PNET)
in one patient and Ewing’s sarcoma in one patient. The
tumor was located in the distal femur in six patients, in the
proximal femur in one patient, and in the proximal tibia in
four patients.
Adjuvant therapy
For osteosarcoma cases, we used the following pre- and
postoperative chemotherapy protocol, developed in coop-
eration with the Department of Pediatrics, for localized
tumors not accompanied by metastasis at the time of initial
consultation.10 This protocol consists of two courses ofTable 1 Data for 11 patients who received an extendable pros
Case Age at surgery (y) Gender Pathological diagnos
1 11 Female Osteosarcoma
2 7 Female PNET
3 12 Male Osteosarcoma
4 10 Female Osteosarcoma
5 11 Male Osteosarcoma
6 7 Male Osteosarcoma
7 16 Female Osteosarcoma
8 8 Male Osteosarcoma
9 12 Male Ewing’s sarcoma
10 12 Female Osteosarcoma
11 16 Female Osteosarcoma
DF Z distal fibula; PF Z proximal fibula; PNET Z primitive neuroectregimen A and two courses of regimen B, followed by
surgery and two postoperative courses of regimens
C þ B þ B and two courses of regimens A þ B þ B. Regimen A
consists of 1.8 g/m2 of ifosfamide for 5 days and 25 mg/m2
adriacin (ADR) for 2 days. Regimen B is high-dose metho-
trexate therapy (12 g/m2, 1 day), and regimen C consists of
120 mg/m2 cisplatin (CDDP) for 1 day and 25 mg/m2 ADR for
3 days. For PNET, pre- and postoperative chemotherapy and
radiotherapy for local control were performed according to
the protocol of the Pediatric Peripheral Blood Stem Cell
Transplantation (PBSCT) Research Group.
Surgery
The resection margins were determined by diagnostic
imaging according to the criteria of Kawaguchi et al.11 In all
patients, extensive resection with a margin 3 cm was
performed.
Extendable prostheses
A growing Kotz type prosthesis was used in six patients
who underwent distal femur replacement and four who
underwent proximal tibia replacement. The component and
stem were unified in all of these prostheses. A Lewis type
prosthesis was used in one patient who underwent proximal
femur replacement. All prostheses were custom-made and
had been designed after determining the resection range by
diagnostic imaging following a single course of preoperative
chemotherapy. Growth was predicted based on the Anderson
and Green growth prediction curve.12 Since the Lewis type
prosthesis has not been approved by the insurance system in
Japan, this type was used only for patients who imported it
after approval from both the hospital and the patient’s
family was obtained (Table 1). Functional evaluations were
performed according to the International Symposium of Limb
Salvage (ISOLS) system,13 as well as X-ray evaluation14 and
assessment of details (such as stem size and length) of the
extendable prosthesis, number of elongation procedures,
length gain, present leg length discrepancy, complications,
and outcome. We used these data to analyze the advantages
and disadvantages of extendable prostheses after resection
of malignant bone tumors in children.thesis.
is Location Implant Follow-up duration (m)
PF Lewis 192
DF Growing Kotz 120
DF Growing Kotz 87
DF Growing Kotz 33
DF Growing Kotz 48
DF Growing Kotz 72
DF Growing Kotz 13
PT Growing Kotz 96
PT Growing Kotz 20
PT Growing Kotz 12
PT Growing Kotz 12
odermal tumor; PT Z proximal tibia.
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Functional evaluation
Functional evaluations were performed according to the
ISOLS system in terms of pain, function, supports, walking,
and gait. Emotional acceptance was excluded because
questions asked of children regarding the degree of satis-
faction tend to be leading, which can make objective
evaluation difficult. The functional score ranged from 52%
to 96% (mean 84%). Patient 11, with a score of 52%, had an
osteosarcoma in the proximal tibia and received walking
training using a knee orthosis after surgery, but developed
lung metastasis approximately 3 months after the operation
and died around 12 months postoperatively. Patients 3, 5, 6
and 7, with scores 90%, had osteosarcoma of the distal
femur (Table 2).
X-Ray evaluation
X-Ray evaluation was performed using the ISOLS system at
the time of final consultation. Bone remodeling results
were excellent in five patients, fair in three patients, and
poor in three patients. The three patients with poor results
(Patients 1, 2 and 8) showed no clinical symptoms such as
pain during walking. The interface result was poor in three
patients, fair in one patient and good in one patient. In
terms of anchorage, fracture of the screw for plate fixation
was observed only in Patient 4. However, since there was no
loosening, the result was regarded as fair (Table 2).
Stem length and thickness
The stem diameter on the femoral side was 8e11 mm
(mean 10.1 mm). Length was determined by measuring
from the stem base to tip of the component and was
80e110 mm (mean 95.1 mm). The stem diameter on the
tibial side was 10e11 mm (mean 10.5 mm). The length was
100 mm in all patients. The amount of bone resected was
130e200 mm (mean 114 mm) on the femoral side and
100e160 mm (mean 132.5 mm) on the tibial side (Table 2).Table 2 Functional and X-ray evaluations and design paramete
Case Functional
score (%)
Bone
remodeling
Interface Anchorage Diameter of
femur side (
1 76 P G E 11
2 80 P P E 10
3 96 E E E 9
4 91 F F F 11
5 96 F E E 8
6 96 F P E 11
7 95 E E E 11
8 76 P P E 11
9 88 E E E 11
10 85 E E E 11
11 52 E E E 11
E Z excellent; F Z fair; G Z good; P Z poor.Anticipated bone growth and present leg-length
discrepancy
The mean anticipated bone growth was 42.9 mm (range
26e86 mm). The mean number of elongating procedures
was 2.8 (range 1e5). Planned lengthening was completed in
only Patients 2, 5 and 6. Elongation was performed via
a small incision made under general anesthesia in all
patients. The amount of lengthening obtained per surgical
elongation procedure was 11.5 mm (range 8.6e13.6 mm).
Leg length discrepancy at the time of final consultation
ranged from 10 mm to 45 mm (mean 29.2 mm). Patient 2 (a
7-year-old female) with PNET of the distal femur who
underwent five elongation procedures was the first in whom
an extendable prosthesis was used in our department. The
total length gain was 43.5 mm, but revision surgery was
performed owing to loosening around the tibial component.
At present, the leg length discrepancy is 45 mm. Patient 1
was an 11-year-old female in whom a Lewis type extend-
able prosthesis was used for the proximal femur. She
underwent two elongation procedures and the total length
gain was 35 mm. However, the leg length discrepancy is still
40 mm. Patient 6, with a sarcoma of the distal femur,
underwent three elongation procedures. Although the
planned length gain was achieved, he, like Patient 2, still
has a substantial leg length discrepancy of 41 mm (Table 3).
Complications
Sinking of the tibial stem due to stem loosening was
observed in two patients, one of whom underwent revision
surgery. Patient 2 showed stem loosening 7 years after the
operation and underwent revision surgery 9 years and 5
months after the initial surgery. Patient 6 showed similar
findings 1 year after the operation, but has been followed
up without further intervention as he does not experience
any disruption to daily living activities. Patient 8 showed
stem loosening around the tibial stem 18 months after wide
resection. He ultimately underwent an above-knee ampu-
tation because of infection.
Patient 8 was an 8-year-old male with a tibial osteo-
sarcoma. Wound swelling was observed after the operation,rs for 11 patients who received an extendable prostheses.
mm)
Femoral stem
length (mm)
Diameter of
tibia side (mm)
Tibial stem
length (mm)
Resection
size (mm)
96 d d 140
90 9 100 200
100 11 125 170
100 9 100 150
100 11 125 130
80 9 100 140
100 10 125 130
117 10 100 120
117 11 100 150
117 10 100 160
117 11 100 100
Table 3 Planned length gain, number of lengthening procedures, length gain, final leg length discrepancy, and complications
for 11 patients who received an extendable prosthesis.
Case Planned length
gain (mm)
Lengthening
procedures
Length
gain
(mm)
Present
discrepancy
(mm)
Complications Outcome
1 50 2 35 40 Stress shielding around the stem CDF
2 43 5 43 45 Revision of the tibial component due to
subsidence of the tibial stem
CDF
3 72 0 0 0 CDF
4 52 1 10 10 CDF
5 32 3 32 10 CDF
6 42 3 41 41 Subsidence of the tibial component CDF
7 32 0 0 0 CDF
8 46 0 0 d Above-knee amputation due to infection CDF
9 76 0 0 d Above-knee amputation due to local recurrence DOD
10 86 0 0 0 Debridement due to wound hematoma CDF
11 26 0 0 0 DOD
CDF Z continuously disease-free; DOD Z died of disease.
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chemotherapy was administered. However, his symptoms
did not improve, so lavage and debridement were per-
formed 18 months after the operation. Since the wound
infection did not subside, he underwent an above-knee
amputation. Patient 10 was a 12-year-old female with tibial
osteosarcoma. She showed postoperative wound hematoma
and underwent debridement 3 weeks after the operation,
which resulted in symptom improvement.
None of our patients showed stem breakage.
Outcomes
Patients 9 and 11 died of lung metastasis. The other
patients have remained disease-free to date.
Discussion
The methods for limb reconstruction after resection of
malignant bone tumors in children vary according to the
site of resection. When diaphyseal lesions are resected, the
affected limb is reconstructed using vascularized fibular
flaps,15 distraction osteogenesis,16 the autoclave method,17
or extracorporeal irradiation18 if the joint can be preserved
in the metaphysis. However, if joint preservation is
impossible due to resection of an extensive area including
the epiphysis, tumor type or extendable prostheses are
used. In patients showing tumor invasion into blood vessels
or nerve fascicles in whom safety margins are difficult to
obtain, reconstruction methods such as rotation plasty19
are indicated for preservation of the affected limb, so
that amputation can be avoided. Whichever method is
selected, limb reconstruction is required to obtain a useful
limb in the future and leg length discrepancy must then be
considered. Extendable prostheses are used when peri-
articular tumors are resected together with the joint.
Scales and Sneath are considered to have been the first to
develop extendable prostheses, in 1976.4 In 1986, Lewis
used extendable prostheses in six children with malignantbone tumors in the USA.2 In 1992, Kotz et al developed an
extendable prosthesis that can be replaced by a Howmed-
ica modular reconstruction system (HMRS) after growth.1,5
In 1998, Schindler developed a custom-made Stanmore
extendable prosthesis and used it in six patients aged 2e12
years with primary malignant bone tumors.6
Extendable prostheses are indicated in patients
approximately 10 years of age with periarticular bone
tumors in whom a leg length discrepancy of no more than
4 cm is expected in the future. The extension mechanism of
extendable prostheses is classified into the invasive type
requiring minor surgery and the noninvasive type in which
the extension mechanism is induced by application of, for
example, an extracorporeal system. The extension mech-
anism of the growing Kotz prosthesis is classified as inva-
sive. The part designed for extension is loosened by
rotating the rocking screw and can be extended by 0.9 mm
by adjusting the screw one turn to the left. The diaphyseal
fixation piece of the part for extension is porous-coated,
while the non-extension part is non-porous. The growing
Kotz prosthesis allows extension with growth and can be
replaced by an HMRS after growth completion.1,5,9 Tumor
type prostheses with a noninvasive extension system have
also been developed. In 2003, Neel et al reported results for
a multicenter study of the Phenix extendable prosthesis,
used as a noninvasive prosthesis in 18 patients.20 An annular
electromagnetic coil compressed using a locking system is
extended by applying an extracorporeal system, which
results in extension of the entire joint prosthesis. Baumgart
et al developed a bio-expandable prosthesis in 2005 and
reported on the MUTARS Xpand expandable tumor pros-
thesis in 2009.8 This expandable prosthesis has a mortar
device in its main portion for extension. These prostheses
are still in the development stage. To establish a stable
extension mechanism, more time may be necessary.
In our experience, the main problems with extendable
prostheses are: (1) age indicated for the prosthesis; (2)
loosening; and (3) infection. The age indicated for
extendable prostheses is 7e14 years (mean 10.1 years) in
the literature, although we found that 7e16 years (mean 11
Extendable prostheses 715years) was appropriate in the present survey. Thus, the
appropriate age is approximately 10 years. If growth of
approximately 4 cm is expected based on the Anderson and
Green growth prediction curves, and age at the time of
extension completion to be w18 years, an age of 12e13
years (at least 10 years) is appropriate for extendable
prostheses.21,22 There are no effective measures against
loosening at present. We observed loosening due to the
extension mechanism of the growing Kotz prosthesis. In two
patients who underwent replacement of the distal femur,
clear loosening was observed around the stem of the tibial
component. One of these patients underwent revision
surgery. The stem of the tibial component for the growing
Kotz prosthesis for the distal femur has a nonporous
coating. The entire component is lifted with tibial growth
after preservation of the tibial diaphysis, which is useful for
leg length correction and facilitates replacement with
conventional tibial components. However, in young chil-
dren, since actual bone growth is difficult to predict, this
component mechanism may sometimes cause loosening. To
prevent loosening, design of the component should take
into consideration growth in the tibial transverse diameter,
and replacement surgery should be planned soon after
limitations in the range of knee motion or pain during
walking are reported. Wound infection did not subside in
one of our four patients with a tibial proximal bone tumor,
and amputation was necessary. In this patient, the growing
Kotz prosthesis for the proximal tibia was too large for the
tibial resection area, and wound closure was difficult in the
first operation, which may have caused infection. For use of
an extendable prosthesis in the proximal tibia, proper
evaluation of the patient’s physique is required because the
soft tissue volume is small.
Extendable prostheses are indicated in Japanese chil-
dren of 10 or more years of age. The optimal age is 12 or 13
years because growth has been completed by the time
lengthening is complete. The distal femur, with adequate
soft tissue covering the entire prosthesis, is the most
appropriate site.
In limb reconstruction after resection of malignant bone
tumors in children, extendable prostheses can be extended
with growth while taking the expected future leg-length
discrepancy into consideration. However, length gain is
limited, and the age and area indicated for these pros-
theses should be adequately evaluated. From our experi-
ence, the optimal candidates for an extendable prosthesis
are children at least 10 years of age with bone tumors in the
distal femur, where the prosthesis can be adequately
covered by soft tissue.References
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